A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
12/2004
12/30/2004	US20040266676 Preventives/remedies for proliferative organ diseases chronic arthritic diseases. hypertrophic scar or keloid
12/30/2004	US20040266003 Using bacterial small membrane vessicles as tools for transfer of heterologous nucleotide sequences into cells
12/30/2004	US20040265998 Using interleukins and colony stimulating factors to convert antigen presenting cells into dendritic cells for use in identifying modulators for treatment of infections, cell proliferative and autoimmune disorders
12/30/2004	US20040265987 Methods of producing influenza vaccine compositions
12/30/2004	US20040265986 Method for the recovery and purification of poxviruses from infected cells
12/30/2004	US20040265976 Antigen and lysine acylated protein; cytokines; drug screening; liquid chromatography
12/30/2004	US20040265975 Method for producing catalytic antibodies (variants), antigens for immunisation and nucleotide sequence
12/30/2004	US20040265968 Tissue plasminogen activator-like protease
12/30/2004	US20040265962 Staphylococcus aureus genes & polypeptides
12/30/2004	US20040265954 Transgenic escherichia for use in the expression and propagation of N-glycosylated target proteins; bioreactors and heterologous protein expression
12/30/2004	US20040265936 In gram-negative host cells; immunogenic epitopes from herpes virus; cytokines; interleukins; interferons; tumour necrosis factors; solid phase synthesis; homologous recombination
12/30/2004	US20040265933 From Streptococcus pneumoniae; antigens, immunogens; shuttle vectors; vaccines; drug screening
12/30/2004	US20040265932 Detecting mRNA which translates into mammaglobin and mucin-like proteins, then detecting cDNA; isolated from Bacillus substilis; solid phase synthesis
12/30/2004	US20040265925 Incubating blood sample, interleukin-3, allergen and physiological buffer, and measuring CD63 expression via flow cytometry; kits; food allergies
12/30/2004	US20040265913 Tumor necrosis factors (TNF); humanized/chimeric monoclonal antibodies; fab fragments; hybridomas, host cells, Chinese Hamster Ovary cells
12/30/2004	US20040265908 use of purified metal binding protein, metallothionein from a brine shrimp (Artemia), to reduce the concentration of a metal in a substrate; bioremediation; pollution control
12/30/2004	US20040265898 C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
12/30/2004	US20040265891 use in diagnosis and treatment of cancer, neurodegenerative, or immune disorders; antibodies for immunoassays; drug screening
12/30/2004	US20040265890 a polypeptide of given amino acid sequence; use as drug target for gastrointestinal disorders; fusion proteins; diagnosis
12/30/2004	US20040265878 Polypeptides and polynucleotides "BASB040" from neisseria meningitidis and vaccine comprising said polypeptides and polynucleotides
12/30/2004	US20040265872 nucleotide sequences for polypeptides of the riboflavin specific deaminase family, "ribG"; drug target for use screening for antibacterials; vectors, host cells
12/30/2004	US20040265866 Receptor on the surface of activated T-cells: ACT-4
12/30/2004	US20040265852 Diangnosis and treatment of AUR1 and/or AUR2 related disorders
12/30/2004	US20040265848 Circovirus sequences associated with piglet weight loss disease (PWD)
12/30/2004	US20040265819 Uricosuric regulating action using protein comprising an amino acid sequence represented by SEQ ID NO:1 or an amino acid sequence derived therefrom being capable of transporting uric acid and its analogs; cardiovascular disorders; gout; hypotensive agents; nucleotide sequences; antibodies; modulators
12/30/2004	US20040265808 Genes involved in osteogenesis, and methods of use
12/30/2004	US20040265804 Method for identifying metastatic tumor cells
12/30/2004	US20040265803 for the prevention, diagnosis and/or therapy of MSI+ tumors; antibodies against the gene product; use as antitumor agents or vaccines
12/30/2004	US20040265792 Agents for treatment of hcv and methods of use
12/30/2004	US20040265367 Liposomes coated with selected antibodies that bind to aminophospholipids
12/30/2004	US20040265342 Desensitizing a patient to polypeptide allergen by administering a peptide derived from allergen to induce a late phase response in an individual who possesses major histocompatibility complex Class II molecule; immunotherapy; vaccines
12/30/2004	US20040265341 Prevention of uveitis
12/30/2004	US20040265340 Emulsan adjuvant immunization formulations and use
12/30/2004	US20040265339 Infectious bronchitis virus vaccine
12/30/2004	US20040265337 Method of generating an immune response and compositions used for same
12/30/2004	US20040265336 Multivalent vaccination using recombinant adenovirus
12/30/2004	US20040265334 Purified or isolated antibody that binds to said outer membrane proteins; accurate diagnosis of ehrlichiosis
12/30/2004	US20040265333 Outer membrane protein of Ehrlichia canis and Ehrlichia chaffeensis
12/30/2004	US20040265332 BASB029 polynucleotide(s) and polypeptides from Neisseria meningitidis
12/30/2004	US20040265331 BASB027 proteins and genes from moraxella catarrhalis, antigens, antibodies, and uses
12/30/2004	US20040265330 Novel compounds
12/30/2004	US20040265329 Administering siderophore receptor polypeptides and porins from gram negative microbes, preferably, lipopolysaccarhide for treating mastitis in a milk producing animal
12/30/2004	US20040265328 Identifying polypeptide antigens that bind to sera raised against commensal bacterial proteins
12/30/2004	US20040265326 Culturing respiratory syncytial virus on cells in a culture medium; separating grown virus from culture medium; solubilizing at least fusion (F) protein, attachment (G) protein and matrix (M) protein from the separated virus; coisolating ,copurifying solubilized RSV proteins; immunogenic
12/30/2004	US20040265325 Human cytomegalovirus antigens expressed in MVA and methods of use
12/30/2004	US20040265323 Compositions comprising pathogen elicited epithelial chemoattractant (eicosanoid hepoxilin A3), inhibitors thereof and methods of use thereof
12/30/2004	US20040265322 Pharmaceutical or food composition for treating pathologies associated with graft rejection or an allergic or autoimmune reaction
12/30/2004	US20040265321 A dimeric fusion protein having two identical polypeptide chains, each chain wtih an extracellular region of an activating Fc gamma R containing an Fc binding site, joined to a molecule that binds an Fc gamma Rn; dimeric fusion protein specifically binds an immune complex
12/30/2004	US20040265320 Administering a compound selected from 3-O-(3',3'-dimethylsuccinyl) betulinic acid, 3-O-(3',3'-dimethylsuccinyl) betulin, 3-O-(3',3'-dimethylglutaryl) betulin, 3-O-(3',3'-dimethylsuccinyl) dihydrobetulinic acid, 3-O-(3',3'-dimethylglutaryl) betulinic acid, (3',3'-dimethylglutaryl) dihydrobetulinic acid
12/30/2004	US20040265317 Methods and compositions useful for inhibition of angiogenesis
12/30/2004	US20040265313 Methods to regulate biofilm formation
12/30/2004	US20040265311 Methods for diagnosing and treating hemostatic disorders by modulating P-selectin activity
12/30/2004	US20040265310 Novel prostate-restricted gene expressed in prostate cancer
12/30/2004	US20040265308 Prevention and treatment of amyloidogenic disease
12/30/2004	US20040265307 Anti-IGF-I receptor antibody
12/30/2004	US20040265303 Anti-CCR2 antibodies and methods of use therefor
12/30/2004	US20040265301 Prevention and treatment of amyloidogenic disease
12/30/2004	US20040265300 Targeting cancer cell; induction or prevention of apoptosis in eukaryotic cells; a fusion peptide contains a viral apoptotic peptide and an antibody fragment; recombinant host cell comprising the vector, encoding chimeric polypeptide; bioassay monitoring apoptosis activity; drug target
12/30/2004	US20040265290 Lactic acid bacteria as agents for treating and preventing allergy
12/30/2004	US20040265278 Moraxella catarrhalis antigen, corresponding gene and uses thereof
12/30/2004	US20040265276 Medicinal combination useful for in vivo exogenic transfection and expression
12/30/2004	US20040265275 Polypeptide
12/30/2004	US20040265274 molecular homolog induces an immune response to the tumor specific protein; tumor receptor is an epidermal growth factor receptor
12/30/2004	US20040265272 Mammalian cell-infecting virus vector encoding epitope-bound beta2m and utilization thereof
12/30/2004	US20040265230 Compositions and methods for diagnosing and treating colon cancers
12/29/2004	WO2004113547A2 Potent combinations of mrna transport elements
12/29/2004	WO2004113540A1 Expression of heterologous protein
12/29/2004	WO2004113518A1 Improvements in virus production
12/29/2004	WO2004113500A2 B7s1: an immune modulator
12/29/2004	WO2004113497A2 Gene delivery to tumors
12/29/2004	WO2004113388A2 Anti alpha - folate - receptor - tetramer antibodies
12/29/2004	WO2004113379A1 Interferon gamma-like protein
12/29/2004	WO2004113377A1 Purification of her-2 variants
12/29/2004	WO2004113374A2 Chlamydia pneumoniae antigens
12/29/2004	WO2004113372A1 MODIFIED BORDETELLA ADENYLATE CYCLASE COMPRISING OR LACKING CD11b/CD18 INTERACTION DOMAIN AND USES THEREOF
12/29/2004	WO2004113370A1 Novel surface protein (hbsag) variant of hepatitis b virus
12/29/2004	WO2004113369A1 Novel surface protein (hbsag) variant of hepatitis b virus
12/29/2004	WO2004112835A2 Suppression of transplant rejection
12/29/2004	WO2004112833A1 Epitope composition for sublingual, buccal or enteric administration prepared by hydrolysis of antigenic structures with chymotrypsin
12/29/2004	WO2004112832A2 Immunogenic compositions comprising multiple gonococcal antigens
12/29/2004	WO2004112829A2 Compositions and methods for the diagnosis and treatment of tumors of glial origin
12/29/2004	WO2004112825A2 Combinations of tumor-associated antigens for the treatment of various types of cancers
12/29/2004	WO2004112717A2 Conjugate for the specific targeting of anticancer agents to cancer cells and production thereof
12/29/2004	WO2004112706A2 Vaccines, immunotherapeutics and methods for using the same
12/29/2004	WO2004112482A2 Biological active coating components, coatings, and coated surfaces
12/29/2004	WO2004099418A8 Fused protein
12/29/2004	WO2004099244A3 Immunogenic human tnf alpha analogues with reduced cytotoxicity and methods of their preparation
12/29/2004	WO2004098578A3 Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
12/29/2004	WO2004096124A3 Compositions and methods for the diagnosis and treatment of tumor
12/29/2004	WO2004084942A3 Methods and means to suppress symptoms of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (gitr or tnfrsf18)
12/29/2004	WO2004082640A3 Human serum albumin conjugates with therapeutic compounds
12/29/2004	WO2004081045A3 Vaccine related to modified apolipoprotein c-iii
12/29/2004	WO2004075875A8 Dosage form having a saccharide matrix
12/29/2004	WO2004053100A3 Immunogenic mutant human immunodeficiency virus gp120 polypeptides, and methods of using same
12/29/2004	WO2004016803A3 Method of enhancing cd4+ t cell responses
12/29/2004	WO2004015072A3 Mrbs as modifiers of the rb pathway and methods of use
12/29/2004	WO2004001014A3 Osteopontin, oligodendrocytes and myelination
12/29/2004	WO2003104429A3 Genes overexpressed by ovarian cancer and their use in developing novel therapeutics
12/29/2004	WO2003086453A8 Purified subfragment codifying for neuroaminidase, recombinant neuroaminidase and its use in zooprophylaxis
12/29/2004	WO2003057146A3 Novel compositions and methods for cancer

1 ... 1096 1097 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 ... 1823